Bloom Science News Today

In cases where standard therapies fail, a medication called XEN1101 reduces seizure frequency by more than 50% in some patients and sometimes eliminates them altogether, a new study shows.

NEW YORK, Oct. 9, 2023 /PRNewswire/ -- In cases where standard therapies fail, an investigational medication called XEN1101 reduces seizure freque...

Research on the gut/brain axis is fueling the development of new therapies for neurological conditions including Dravet syndrome, ALS, and autism-related irritability.

/PRNewswire/ -- Bloom Science, Inc., a clinical-stage, central nervous system (CNS) company focused on discovering and developing breakthrough therapeutics...

Scientists have decoded the genetic makeup of Akkermansia, a gut bacterium that could help manage cholesterol levels.

Scientists at Duke University School of Medicine are the first to decode the genetic makeup of Akkermansia, a gut bacterium that could help manage cholesterol levels and be used as a next-generation probiotic.   Akkermansia thrives in the mucus layer of the intestine and has a knack for breaking down a type of sugary protein called mucin. This unique skill could be important for our health.   When Akkermansia is present in the right amounts, it’s associated with better metabolic and immune...

FinSMEs is the financial news site dedicated to covering venture capital, private equity, and merger and acquisition deals in real time!

San Diego=based Bloom Science, a biotech startup developing microbiome-based treatments for neurological and inflammatory disease, says it has raised $12M in its Series A funding. The funding was led

/PRNewswire-HISPANIC PR WIRE/ -- San Diego based biotech company Bloom Science announced today it successfully closed a USD $12 Million Series A financing with...